about
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaCombined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.Towards individualized follow-up in adult acute myeloid leukemia in remission.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.Fatal haemolytic crisis with microvascular pulmonary obstruction mimicking a pulmonary embolism in a young African man with glucose-6-phosphate dehydrogenase deficiency.Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology.The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy.Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.The minimal residual disease concept coming of age - now for the direct comparison of methodologies.Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms.Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemiaRelapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgeneGenetic and epigenetic similarities and differences between childhood and adult AMLPersistent altered fusion transcript splicing identifiesRUNX1-RUNX1T1+ AML patients likely to relapse[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]
P50
Q26770394-97CFD419-A6F9-499F-B51D-05B856BC57AAQ28087291-4328300F-2AA3-4528-AF9B-44153341FF04Q36177937-F66635FB-6196-4417-BE44-497D6A597E5CQ36964344-BC17E350-725F-4C73-A269-F7AA2A12D326Q37811623-8478B98D-1A80-4CEF-9637-78E7FAD6F7BCQ38022075-842712A3-D9FA-4FE7-967F-1A3D786FB928Q38762368-FFACF3DA-8F2E-497B-9E6F-43D314B63587Q39930852-A238333D-FA21-452D-8A44-08262CD6FBCFQ41553306-A916D3A7-A804-4B05-A870-0D6634CAFAEEQ44222759-CFE92995-81CD-4F64-9E7C-B54AF3C3C492Q44443847-921C850F-E759-4D77-8E68-886DDC5FA302Q44703694-D0781F29-6CAD-4A84-84CE-551A1D03F65AQ46099641-F36D29AB-3167-41F9-842D-C6C59C38F45CQ46143934-15453C7A-38D2-403D-8008-DEB874D72602Q47155862-631901A0-4EFC-4DDC-8698-91498433BCE1Q51888520-9BECC8A0-3CEC-4A2F-910A-26FF6E6045BFQ54204813-73B56649-E2E0-4E0C-ADFE-11C342B1A67DQ54328251-28080448-D793-453C-8F49-7B4DB0CE6A56Q54465378-FCED802B-D0AF-4C1B-AB62-099239439C54Q55057743-E0A62032-9F39-410E-A37F-31B862E8357AQ57415017-D69F0955-5DAE-4DFC-873D-537FADF44C49Q59194210-1F89C5C6-DBB6-427A-8C72-09BD8735B7FCQ59194230-169D44CC-248A-4FCC-AF50-9E84A9B3A207Q59194237-16A96591-75D5-4822-B2A8-BDCF1D78CA64Q59194238-EFBB29F1-F30E-42AC-980F-CB16378AA10D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hans Beier Ommen
@ast
Hans Beier Ommen
@en
Hans Beier Ommen
@es
Hans Beier Ommen
@nl
Hans Beier Ommen
@sl
type
label
Hans Beier Ommen
@ast
Hans Beier Ommen
@en
Hans Beier Ommen
@es
Hans Beier Ommen
@nl
Hans Beier Ommen
@sl
prefLabel
Hans Beier Ommen
@ast
Hans Beier Ommen
@en
Hans Beier Ommen
@es
Hans Beier Ommen
@nl
Hans Beier Ommen
@sl
P106
P21
P31
P496
0000-0001-7628-8694